Induction of the IL-13 receptor α2-chain by IL-4 and IL-13 in human keratinocytes:: involvement of STAT6, ERK and p38 MAPK pathways

被引:90
作者
David, M
Ford, D
Bertoglio, J
Maizel, AL
Pierre, J
机构
[1] INSERM, Fac Pharm, U461, F-92296 Chatenay Malabry, France
[2] Boston Univ, Sch Med, Roger Williams Med Ctr, Providence, RI 02908 USA
关键词
keratinocytes; MAP kinase; inhibitors; IL-4; IL-13; cytokine receptor chain; transduction;
D O I
10.1038/sj.onc.1204629
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
IL-4 and IL-13 are related cytokines which induce both pro- and anti-inflammatory effects depending on the cell type they act upon and the nature of the receptors expressed. The type I receptor complex is composed of the IL-4R alpha and gammac and only binds IL-4, whereas, in the type II receptor, IL-4R alpha dimerizes with IL-13R alpha1 upon either IL-4 or IL-13 binding. Another ligand binding chain potentially implicated in the IL-4/M-13 receptor has been described, the IL-13R alpha2, but the regulation of its expression and its role in IL-4/IL-13 transduction is poorly understood. In this study we report that IL-4 and IL-13 upregulate IL-13R alpha2 at both the mRNA and protein levels in the keratinocyte cell line HaCaT. In these cells, IL-4 or IL-13 were shown to activate the Janus Kinases JAK1 and JAK2, the transcription factor STAT6, and the ERK and p38 mitogen-activated protein kinases. We show that IL-4 or IL-13-induced IL-13R alpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580. Moreover, expression of a constitutive active mutant of STAT6 alone did not modify IL-13R alpha2 mRNA expression, but potentiated the effects of IL-4 or 11-13 on IL-13 alpha2 expression. The constitutive active mutants of MEK1 or MKK6 increased the level of expression of IL-13R alpha2 mRNA even in absence of stimulation. Our findings demonstrate, for the first time, that IL-4 and IL-13 can induce IL-13R alpha2 expression in keratinocytes, and that the ERK and p38 MAPK together with JAK2 and STAT6 play a critical role in this process.
引用
收藏
页码:6660 / 6668
页数:9
相关论文
共 41 条
[1]   cDNA cloning and characterization of the human interleukin 13 receptor alpha chain [J].
Aman, MJ ;
Tayebi, N ;
Obiri, NI ;
Puri, RK ;
Modi, WS ;
Leonard, WJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (46) :29265-29270
[2]   NORMAL KERATINIZATION IN A SPONTANEOUSLY IMMORTALIZED ANEUPLOID HUMAN KERATINOCYTE CELL-LINE [J].
BOUKAMP, P ;
PETRUSSEVSKA, RT ;
BREITKREUTZ, D ;
HORNUNG, J ;
MARKHAM, A ;
FUSENIG, NE .
JOURNAL OF CELL BIOLOGY, 1988, 106 (03) :761-771
[3]  
BRUNET A, 1994, ONCOGENE, V9, P3379
[4]   Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain [J].
Caput, D ;
Laurent, P ;
Kaghad, M ;
Lelias, JM ;
Lefort, S ;
Vita, N ;
Ferrara, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16921-16926
[5]   Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway [J].
Chen, CY ;
Del Gatto-Konczak, F ;
Wu, ZG ;
Karin, M .
SCIENCE, 1998, 280 (5371) :1945-1949
[6]   INTERLEUKIN-4 AMPLIFIES MONOCYTE CHEMOTACTIC PROTEIN AND INTERLEUKIN-6 PRODUCTION BY ENDOTHELIAL-CELLS [J].
COLOTTA, F ;
SIRONI, M ;
BORRE, A ;
LUINI, W ;
MADDALENA, F ;
MANTOVANI, A .
CYTOKINE, 1992, 4 (01) :24-28
[7]   SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1 [J].
CUENDA, A ;
ROUSE, J ;
DOZA, YN ;
MEIER, R ;
COHEN, P ;
GALLAGHER, TF ;
YOUNG, PR ;
LEE, JC .
FEBS LETTERS, 1995, 364 (02) :229-233
[8]   A gain-of-function mutation in STAT6 [J].
Daniel, C ;
Salvekar, A ;
Schindler, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (19) :14255-14259
[9]   Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells [J].
Debinski, W ;
Miner, R ;
Leland, P ;
Obiri, NI ;
Puri, RK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (37) :22428-22433
[10]   INTERLEUKIN-13 IS A B-CELL STIMULATING FACTOR [J].
DEFRANCE, T ;
CARAYON, P ;
BILLIAN, G ;
GUILLEMOT, JC ;
MINTY, A ;
CAPUT, D ;
FERRARA, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (01) :135-143